[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-348968-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-348968-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","profiling-ten-rho-gtpases-in-myeloid-malignancies-reveals-distinct-expression-patterns-and-prognostic-associations","Profiling Ten RHO GTPases in Myeloid Malignancies Reveals Distinct Expression Patterns and Prognostic Associations","","The RHO GTPase family controls cytoskeleton-dependent functions such as proliferation and migration. While dysregulation is documented in solid tumors, its relevance to hematologic malignancies remains limited. The study measured ten RHO GTPase gene expression in bone marrow from acute myeloid leukemia (AML) and myelodysplastic neoplasms (MDS), and used TCGA AML data to assess prognostic links. RHOBTB2, RND2, and RHOQ differed from healthy controls, and RHOBTB2 predicted worse overall and disease-free survival, including intermediate-risk AML. Results support RHOBTB2 as a candidate AML prognostic biomarker and motivate functional validation in leukemogenesis.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/profiling-ten-rho-gtpases-in-myeloid-malignancies-reveals-distinct-expression-patterns-and-prognostic-associations/348968/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/profiling-ten-rho-gtpases-in-myeloid-malignancies-reveals-distinct-expression-patterns-and-prognostic-associations/348968.png","ImageObject",300,407,{"name":42,"@type":43},"Sophia Brooks","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-12","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",17,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Which RHO GTPase genes showed differential expression compared with healthy controls?","Question",{"text":63,"@type":64},"RHOBTB2, RND2, and RHOQ were differentially expressed versus healthy controls.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How is RHOBTB2 associated with patient outcomes?",{"text":68,"@type":64},"RHOBTB2 elevation was seen in both MDS and AML and was linked to inferior overall and disease-free survival, including in intermediate-risk AML.",{"name":70,"@type":61,"acceptedAnswer":71},"What diseases and datasets were analyzed in the study?",{"text":72,"@type":64},"The study analyzed bone marrow samples from AML and MDS patients and also assessed prognostic associations using TCGA AML data.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},348968,1790171059,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":112,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":118,"preview_page_count":33,"preview_urls":145},962084925636,"https://ap-avatar.wpscdn.com/davatar_994ba38a5ba835b3df7d355c54d3ed8d","Cancer Medicine  \n| \u003Cbr>\u003Cbr>Profiling Ten RHO GTPases in Myeloid Malignancies Reveals Distinct Expression Patterns and\u003Cbr>Prognostic Associations\u003Cbr>Beatriz de Almeida Rodrigues1 | Luciana Bueno de Paiva2 | Maria Carolina Clares Ramalho1 | Amanda Ferreira Damasceno1 | Sara Teresinha Olalla Saad2 | Mariana Lazarini1 \u003Cbr>1Department of Clinical and Experimental Oncology, Federal University ofSão Paulo (UNIFESP), São Paulo, Brazil | 2Hematology and Blood Transfusion Center, National Institute of Science and Technology of Blood (INCTS), University of Campinas (UNICAMP), Campinas, Brazil\u003Cbr>Correspondence: Mariana Lazarini ([lazarini@unifesp.br](lazarini@unifesp.br))\u003Cbr>Received: 19 September 2025 | Revised: 12 March 2026 | Accepted: 20 March 2026\u003Cbr>Keywords: acute myeloid leukemia | myelodysplastic neoplasms | RHO GTPases | RHOBTB2 |  |\n| --- | --- |\n| ABSTRACT\u003Cbr>The RHO GTPase family regulates cytoskeleton-dependent processes, including proliferation and migration. Although their dysregulation is well described in solid tumors, little is known about their role in hematologic malignancies. We investigated the expression of ten RHO GTPase genes in bone marrow samples from patients with acute myeloid leukemia (AML) and myelodysplastic neoplasms (MDS) and analyzed TCGA AML data for prognostic associations. RHOBTB2, RND2, and RHOQ were differentially expressed compared with healthy controls. RHOBTB2 was elevated in both MDS and AML and associated with inferior overall and disease-free survival, including in intermediate-risk AML. Our findings reveal distinct dysregulation patterns of RHO GTPases in myeloid malignancies and confirm RHOBTB2 as a candidate prognostic marker in AML with a potential oncogenic role. These data support further investigation into the functional roles of RHO GTPases in leukemogenesis and their utility as emerging biomarkers in hematologic cancers. |  |\n| Acute myeloid leukemia (AML) is a severe hematological malignancy characterized by impaired blood cell production due to | Myelodysplastic neoplasms (myelodysplastic syndromes or MDS) comprise a group of hematological disorders with cytolog- |\n| the abnormal growth of immature hematopoietic cells (myeloid blasts) in the bone marrow. AML typically affects adults, with | ical dysplasia in the bone marrow and a risk of evolution to AML [5]. Approximately 20% of newly diagnosed AML cases progress |\n| a median age of diagnosis of 69 years [1] . The estimated 5-year overall survival (OS) rate can range from 40% to 50% in young | from MDS (AML with myelodysplasia-related changes or AMLMRC) [6] . Poor prognosis of AML-MRC is related to escape of |\n| patients, while patients over the age of 60 show an average 5- | apoptosis, elevated percentages of myeloblasts in the bone mar- |\n| year OS rate of 20% to 30%[2] . | row and specific genetic abnormalities [7, 8] . |\n| Most AML cases occur without predisposing conditions (de novo) . However, AML can also arise secondary to prior chemo- | New treatment options for AML have been approved since 2017 for patients ineligible for standard chemotherapy [3] . However, |\n| therapy for unrelated malignancies or as a progression from | approximately 10% to 40% of newly diagnosed patients with |\n| other hematologic neoplasms [3] . Secondary AML cases are | AML do not achieve complete remission with intensive induc- |\n| associated with worse clinical outcomes compared to de novo | tion therapy, and most patients relapse [9, 10] . In addition, the |\n| AML [4] . | current therapy for MDS is not curative [11] . Therefore, the |\n| Beatriz de Almeida Rodrigues and Luciana Bueno de Paiva contributed equally to this manuscript. |  |\n| This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.\u003Cbr>© 2026 The Author(s). Cancer Medicine published by John Wiley & Sons Ltd. |  |\n\nCancer Medicine, 2026; 15:","cbCaia3NzQKCgU3D","https://ap.wps.com/l/cbCaia3NzQKCgU3D","pdf",936867,"English","# Abstract\n## Background and rationale\n## Study aim and approach\n## Patient cohorts and sample sources\n## Methods outline","[{\"question\":\"Which RHO GTPase genes showed differential expression compared with healthy controls?\",\"answer\":\"RHOBTB2, RND2, and RHOQ were differentially expressed versus healthy controls.\"},{\"question\":\"How is RHOBTB2 associated with patient outcomes?\",\"answer\":\"RHOBTB2 elevation was seen in both MDS and AML and was linked to inferior overall and disease-free survival, including in intermediate-risk AML.\"},{\"question\":\"What diseases and datasets were analyzed in the study?\",\"answer\":\"The study analyzed bone marrow samples from AML and MDS patients and also assessed prognostic associations using TCGA AML data.\"}]","Profiling Ten RHO GTPases in Myeloid Malignancies Reveals Distinct Expression Patterns and Prognostic Associations | PDF",1790080941,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d34c13cc3481d5fe7f3a28a71e699c41.webp",983,1291,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/85ddf35aaf59166fe2cc6cb2809b96c4.webp",982,1290,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/30acd7935e9e83cda44143a4fa706e98.webp",981,1289,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9cd83e837e201bb24d02f33de0682c13.webp",980,1287]